UroGen Pharma (URGN) Net Cash Flow (QoQ) (2017 - 2026)
UroGen Pharma (URGN) Net Cash Flow (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -103.86% |
| Dec 31, 2025 | 896.46% |
| Sep 30, 2025 | 76.63% |
| Jun 30, 2025 | 83.63% |
| Mar 31, 2025 | -244.36% |
| Dec 31, 2024 | 149.65% |
| Sep 30, 2024 | -207.09% |
| Jun 30, 2024 | 142.96% |
| Mar 31, 2024 | 249.96% |
| Dec 31, 2023 | -124.50% |
| Sep 30, 2023 | 704.34% |
| Jun 30, 2023 | 13.01% |
| Mar 31, 2023 | -170.60% |
| Dec 31, 2022 | 151.39% |
| Sep 30, 2022 | -112.90% |
| Jun 30, 2022 | -140.48% |
| Mar 31, 2022 | 649.71% |
| Dec 31, 2021 | -37.49% |
| Sep 30, 2021 | -134.97% |
| Jun 30, 2021 | 284.51% |